-+ 0.00%
-+ 0.00%
-+ 0.00%

ALK’s tree pollen and house dust mite tablets now recommended by NICE for paediatric treatment in the UK health system

Barchart·08/14/2026 05:23:00
Listen to the news

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the company’s tree pollen tablet (ITULAZAX®) and house dust mite tablet (ACARIZAX®) for children with moderate to severe allergic rhinitis whose symptoms are not controlled by symptomatic treatment. ITULAZAX® is recommended for children aged 5 to 17 with birch pollen allergy and ACARIZAX® for children aged 5 to 11 with house dust mite allergy, making both tablets available to eligible children through the National Health Service (NHS).

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.